Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals, a specialty pharmaceutical company, has announced that its subsidiary Watson Laboratories, has filed a lawsuit in the US District Court of Delaware against Barr Pharmaceuticals and its subsidiary Barr Laboratories for infringement of patents listed in the Orange Book for Watson's product Oxytrol.
Subscribe to our email newsletter
The lawsuit is based upon an abbreviated new drug application (ANDA) filed by Barr requesting approval to market and sell a generic version of Oxytrol to be sold in the US prior to the expiration of the Orange Book listed patents.
In its notice letter to Watson, Barr alleges that patents covering Oxytrol are invalid, unenforceable or will not be infringed by Barr’s manufacture, use or sale of the product described in its ANDA.
The filing of this lawsuit is provided for by the Hatch-Waxman Act, a federal statute governing certain aspects of generic drug approvals. Under that statute, the filing of the lawsuit stays any FDA approval of the Barr ANDA until the earlier of a district court judgment in favor of Barr or 30 months from Watson’s receipt of Barr’s notice letter.